Mar 4, 2026 05:05PM
Feb 24, 2026 04:01PM
Feb 11, 2026 07:30AM
Feb 11, 2026 07:30AM
Feb 4, 2026 04:01PM
Jan 12, 2026 07:45AM
Jan 11, 2026 02:00PM Stoke Therapeutics accelerates Phase 3 trial timeline for Dravet drug
Jan 11, 2026 02:00PM
Jan 5, 2026 04:34AM
Dec 5, 2025 09:01AM
Dec 5, 2025 09:00AM
Dec 5, 2025 09:00AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Nov 4, 2025 04:01PM
Oct 20, 2025 07:30AM
Oct 13, 2025 01:34PM
Oct 9, 2025 04:31PM
Oct 9, 2025 04:30PM
Oct 9, 2025 04:30PM
Sep 2, 2025 07:03AM Biogen and Stoke present three-year zorevunersen data for Dravet syndrome
Sep 2, 2025 07:01AM
Sep 2, 2025 07:00AM
Sep 2, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 25, 2025 07:00AM
Aug 18, 2025 05:11AM Stoke Therapeutics (STOK) PT Lowered to $28 at BTIG
Aug 12, 2025 04:01PM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Aug 11, 2025 07:00AM
Jul 18, 2025 02:02AM
Jul 14, 2025 06:57AM H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)
Jul 10, 2025 07:00AM
Jul 10, 2025 07:00AM
May 13, 2025 07:00AM
Mar 18, 2025 07:00AM
Mar 18, 2025 06:58AM
Mar 18, 2025 06:58AM
Feb 18, 2025 09:58AM BTIG Reiterates Buy Rating on Stoke Therapeutics (STOK)
Feb 18, 2025 08:03AM
Feb 18, 2025 08:00AM
Jan 8, 2025 06:36AM
Jan 7, 2025 07:02AM
Jan 7, 2025 07:00AM
Jan 6, 2025 04:30PM
Dec 6, 2024 12:00PM Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Dec 4, 2024 07:01AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All